Synthetic pentadecapeptide
BPC-157
An investigational peptide with a sizable preclinical literature, early human work, and a large gap between biological signal and proven clinical effect.
Also known as BPC 157 · Body Protection Compound 157 · pentadecapeptide BPC 157
01 · Evidence profile
One molecule, four evidence questions
Small uncontrolled pilots cannot establish a patient benefit.
Human exposure and pharmacokinetic characterization remain sparse.
The human safety dataset is too small for confident risk estimates.
No validated approved formulation; identity and purity vary outside formal research.
02 · Identity
What it is
BPC-157 is a synthetic 15-amino-acid peptide promoted online for injury recovery and other uses. Popularity, testimonials, animal findings, and availability are not evidence of an approved or proven human treatment.
03 · Product identity
The molecule is not the finished product.
A peptide sequence, a nominated bulk substance, a clinical-study product, and a consumer vial are separate evidence objects. Identity and product quality cannot be assumed from the name.
None identified in the United States.
- No FDA-approved indication
04 · Evidence snapshot
What the evidence can and cannot say
The preclinical literature contains positive signals in cell and animal models, including tendon-healing models. Small human pilot work and registered clinical research now exist, but do not establish a clinical effect in people. FDA's July 2026 PCAC briefing evaluated BPC-157-related bulk substances for a nominated ulcerative-colitis use and documented evidence and safety gaps. That advisory-stage record supports scrutiny; it is not a final FDA determination.
The available evidence still does not establish that BPC-157 safely heals sports injuries or other conditions in people. Early, uncontrolled, or registered research is not the same as a replicated patient benefit, and a trial listing is not a positive result.
05 · Claim check
Three claims under the lens
“BPC-157 improves tendon healing in preclinical models.”
Cell and rat tendon studies report positive healing signals. The scope matters: these results support biological plausibility, not a proven human treatment.
- Evidence basis
- Preclinical evidence
- Scope
- Cell and animal tendon models only; not clinical healing outcomes in people.
“BPC-157 heals tendons and muscles in people.”
Early human work is too small and limited to establish efficacy. Reliable, replicated human outcome evidence is still needed.
- Evidence basis
- No reliable human outcome evidence
- Scope
- Human tendon and muscle-healing claims; existing pilots and a trial registration do not establish benefit.
“Athletes can use it because it is not a steroid.”
WADA lists BPC-157 under S0 non-approved substances, prohibited at all times for covered athletes.
- Evidence basis
- Regulatory or product record
- Scope
- Athletes subject to the current WADA Code and their applicable governing-body rules.
06 · Safety boundary
Before this becomes personal
The site will not provide self-injection, reconstitution, dosing, sourcing, or stack instructions. “Research use only” does not establish quality or make a product appropriate for human use.
BPC-157 is listed under WADA's S0 non-approved substances category and is prohibited at all times for covered athletes.
Reviewed 2026-07-23. This status is not personal clearance to compete.Check the governing record ↗07 · Sources
Check the primary record
08 · Provenance
Review history
Updated around FDA's July 2026 briefing and explicit product-identity boundaries.
Responsible editor: Anthony Treviso. Editorial source review completed. This page has not been independently medically reviewed by a physician or pharmacist.